Phibro Animal Health Corp

Phibro Animal Health Corp(PAHC)股票分析

$38.800

-0.986 (-2.54%)收盘时

Loading chart…
最高
39.510
开盘
39.510
成交量加权均价
38.98
成交量
102.86K
市值
696.66M
最低
38.620
成交额
4.01M
企业价值/息税折旧摊销前利润(TTM)
10.41

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

AI 分析 of Phibro Animal Health Corp (PAHC)

买入

Phibro Animal Health Corp (PAHC) is a good buy right now due to its strong financial performance, highlighted by a 17% increase in total sales for FY 2026, reaching $1.52 billion, and a significant 37% rise in adjusted net income for Q4 2026 to $35 million. The current price of $38.80 is below the analyst price target of $44, suggesting a potential upside of 13.5%. However, the main risk is the regulatory headwinds that could impact future earnings, as indicated by the downgrade from Citi.

分析师评级(6)

上行空间 +22.42%
卖出
1 买入
2 持有
3 卖出
当前: 38.80
最低
45.00
平均
47.50
最高
50.00

Citi

2026-05-14

目标价

$44

中性

Citi

2026-05-13

目标价

$44

中性

Citi

2026-04-15

目标价

$62

中性

Morgan Stanley

2026-02-06

目标价

$49

Equal Weight

JPMorgan

2025-11-07

目标价

$50

增持

估值指标

Phibro Animal Health Corp(PAHC)当前预期市盈率为 13.83,5 年平均预期市盈率为 12.60。

预期市盈率

合理
5 年均值 P/E
12.60
当前P/E
13.83
高估
14.86
低估
10.35

预期 EV/EBITDA

高估
5 年均值 EV/EBITDA
8.80
当前EV/EBITDA
10.41
高估
10.04
低估
7.56

预期市销率

合理
5 年均值 P/S
0.76
当前P/S
0.99
高估
1.00
低估
0.53

持有 PAHC 的大户

C

Castleknight Management LP

+ 持有PAHC

-1.82%

3个月收益率

事件时间线

2026-08-26 (ET)

20:00:00

Salesforce Shares Rise 12.8% After Earnings Boost

16:30:00

Sees FY27 Revenue of $1.55B to $1.6B

16:30:00

Phibro Animal Health Q4 Revenue $396.7M Beats Expectations

2026-05-06 (ET)

16:50:00

Raises FY26 Revenue Outlook to $1.46B-$1.5B

16:40:00

Phibro Animal Health Reports Q3 Revenue of $383.5M

资讯

PAHC 常见问题 —— 由 Alphio AI 解答

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phibro Animal Health Corp (PAHC) is a good buy right now due to its strong financial performance, highlighted by a 17% increase in total sales for FY 2026, reaching $1.52 billion, and a significant 37% rise in adjusted net income for Q4 2026 to $35 million. The current price of $38.80 is below the analyst price target of $44, suggesting a potential upside of 13.5%. However, the main risk is the regulatory headwinds that could impact future earnings, as indicated by the downgrade from Citi.

6 analysts cover PAHC: 1 rate it Buy, 2 Hold and 3 Sell. The average price target is 47.50.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易